These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 26494300)
1. Bone stroma-derived cells change coregulators recruitment to androgen receptor and decrease cell proliferation in androgen-sensitive and castration-resistant prostate cancer cells. Villagran MA; Gutierrez-Castro FA; Pantoja DF; Alarcon JC; Fariña MA; Amigo RF; Muñoz-Godoy NA; Pinilla MG; Peña EA; Gonzalez-Chavarria I; Toledo JR; Rivas CI; Vera JC; McNerney EM; Onate SA Biochem Biophys Res Commun; 2015 Nov; 467(4):1039-45. PubMed ID: 26494300 [TBL] [Abstract][Full Text] [Related]
2. Altered corepressor SMRT expression and recruitment to target genes as a mechanism that change the response to androgens in prostate cancer progression. Godoy AS; Sotomayor PC; Villagran M; Yacoub R; Montecinos VP; McNerney EM; Moser M; Foster BA; Onate SA Biochem Biophys Res Commun; 2012 Jul; 423(3):564-70. PubMed ID: 22695118 [TBL] [Abstract][Full Text] [Related]
3. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Agoulnik IU; Vaid A; Nakka M; Alvarado M; Bingman WE; Erdem H; Frolov A; Smith CL; Ayala GE; Ittmann MM; Weigel NL Cancer Res; 2006 Nov; 66(21):10594-602. PubMed ID: 17079484 [TBL] [Abstract][Full Text] [Related]
4. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Gregory CW; Johnson RT; Mohler JL; French FS; Wilson EM Cancer Res; 2001 Apr; 61(7):2892-8. PubMed ID: 11306464 [TBL] [Abstract][Full Text] [Related]
5. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Shafi AA; Yen AE; Weigel NL Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952 [TBL] [Abstract][Full Text] [Related]
6. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells. Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071 [TBL] [Abstract][Full Text] [Related]
7. Androgen ablation elicits PP1-dependence for AR stabilization and transactivation in prostate cancer. Liu X; Han W; Gulla S; Simon NI; Gao Y; Liu J; Wang L; Yang H; Zhang X; Chen S Prostate; 2016 May; 76(7):649-61. PubMed ID: 26847655 [TBL] [Abstract][Full Text] [Related]
8. Androgen Receptor Coactivators in Regulation of Growth and Differentiation in Prostate Cancer. Culig Z J Cell Physiol; 2016 Feb; 231(2):270-4. PubMed ID: 26201947 [TBL] [Abstract][Full Text] [Related]
9. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells. Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564 [TBL] [Abstract][Full Text] [Related]
10. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells. Colditz J; Rupf B; Maiwald C; Baniahmad A Mol Cell Biochem; 2016 Oct; 421(1-2):139-47. PubMed ID: 27562825 [TBL] [Abstract][Full Text] [Related]
11. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Hodgson MC; Astapova I; Hollenberg AN; Balk SP Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755 [TBL] [Abstract][Full Text] [Related]
12. Cell-line and tissue-specific signatures of androgen receptor-coregulator transcription. Bebermeier JH; Brooks JD; DePrimo SE; Werner R; Deppe U; Demeter J; Hiort O; Holterhus PM J Mol Med (Berl); 2006 Nov; 84(11):919-31. PubMed ID: 16932916 [TBL] [Abstract][Full Text] [Related]
13. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth. Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860 [TBL] [Abstract][Full Text] [Related]
14. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation. Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789 [TBL] [Abstract][Full Text] [Related]
15. Stromal-epithelial cell interactions and androgen receptor-coregulator recruitment is altered in the tissue microenvironment of prostate cancer. Cano P; Godoy A; Escamilla R; Dhir R; Onate SA Cancer Res; 2007 Jan; 67(2):511-9. PubMed ID: 17234758 [TBL] [Abstract][Full Text] [Related]
16. Characterization of allosteric modulators that disrupt androgen receptor co-activator protein-protein interactions to alter transactivation-Drug leads for metastatic castration resistant prostate cancer. Fancher AT; Hua Y; Close DA; Xu W; McDermott LA; Strock CJ; Santiago U; Camacho CJ; Johnston PA SLAS Discov; 2023 Oct; 28(7):325-343. PubMed ID: 37549772 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens. Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455 [TBL] [Abstract][Full Text] [Related]
18. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells. Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555 [TBL] [Abstract][Full Text] [Related]